-
17Sept. 2025
13.25-13.30 pm - Opening
Eric Deutsch, phD, MD
Director of Gustave Roussy Radiation Oncology Department and INSERM UMR 103013.25-13.30 pm: OPENING
Welcome and introduction
PRIMER ON RADIATIONS, CANCER IMMUNOLOGY AND IMMUNOTHERAPY
13.30-15.30 Session I:
Cancer immunology and Immunotherapy
(Oliver Kepp)
13.30-14.00: Innate Immunity,
TBD
14.00-14.30: Adaptive Immunity,
TBD
14.30-15.00: Immune Metabolism,
Pr Guido Kroemer,
Cordeliers Research Center, FR
15.00-15.30: Immunogenic cell death and autophagy,
Dr Lorenzo Galluzzi,
Weill Cornell Medicine, USA
15.30-16.00: Coffee break and exhibition
16.00-18.00 Session II:
Radiation dose, modalities and resistance
(François de Kermengy)
16.00-16.30: Charged particles radiotherapy,
Pr Marco Durrante,
German Cancer Research Center, G16.30-17.00:
TBD17.00-17.30: Next generation approaches in radiotherapy,
Pr Amir Abdollahi,
NCT Heidelberg, G17.30-18.00: Fatty acid metabolism and radiation-induced anti-tumor immunity,
Dr Claire Vanpouille-Box
Weill Cornell Medicine, USA18.00-20.00
Cocktail poster session and exhibition
-
18Sept. 2025
MAIN PROGRAM
8.30-10.00 Session III:
Myeloid cells
(Paul Bergeron)
8.30-9.00: Sepsis-trained macrophages promote antitumoral tissue-resident T cells,
Pr Antoine Roquilly,
Nantes University, FR9.00-9.30: TBD
9.30-10.00: Dendritic cells as shepherds of T cell immunity in cancer,
Dr Mikael Pittet,
University of Geneva, SW10.00-10.30 Coffee break and exhibition
10.30-12.30 Session IV:
Immunosuppression
(Michele Mondini)
10.30-11.00: Microenvironmental reorganization in brain tumors following radiotherapy and recurrence revealed by hyperplexed immunofluorescence imaging,
Pr Johanna Joyce,
University of Lausanne, SW11.00-11.30: Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer,
Dr Fatima Mechta-Grigoriou,
Institut Curie, FR11.30-12.00: Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1,
Dr Monica Olcina,
University of Oxford, UK12.00-12.30: Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites,
Pr Ralph Weichselbaum,
Chicago University, USA12.30-14.00 Lunch break and exhibition
14.00-16.00 Session V:
DNA damage
(Marco)
14.00-14.30: The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy,
Pr Sandra Demaria,
Weill Cornell Medicine, USA14.30-15.00: TBD
15.00-15.30: T-cell receptor determinants of response to chemo-radiation in locally-advanced HPV16-driven malignancies,
Pr Kevin Harrington,
ICR, UK15.30-16.00: Micronuclei induced by radiation, replication stress, or chromosome segregation errors do not activate cGAS-STING,
Dr Crispin Hiley,
UCL Cancer Institute16.00-16.30 coffee break and exhibition
16.30-18.00 Session VI:
Next generation Immunotherapy
(Marie Morfouace)
16.30-17.00: Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma,
Dr Jerome Galon,
Cordeliers Research Center, FR17.00-17.30: TBD
17.30-18.00: New immune-based approaches in the clinic,
Pr Fabrice Barlési,
Gustave Roussy, FR20.00-00.00
Gala dinner
-
19Sept. 2025
8.30-10.0 Session VII:
Tumor Microenvironment
(Marine Fidelle/Carolina da Silva)
8.30-9.00: Mechanisms regulating T-cell infiltration and activity in solid tumors,
Pr George Coukos,
CHUV, SW9.00-9.30: Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease,
Pr Martin Pruschy,
University Hospital Zurich9.30-10.00: Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1,
Pr Tim Illidge,
Manchester Cancer Research Center, UK10.00-10.30 Coffee break and exhibition
10.30-12.30 Session VIII:
AI, Imaging and Radiomics
(Ibrahim Bouakka)
10.30-11.00: First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET,
Pr Idris Bahce,
VUMC, NL11.00-11.30: Translational frontiers and clinical opportunities of immunologically-fitted radiotherapy,
Pr Eric Deutsch,
Gustave Roussy, FR11.30-12.00: TBD
12.00-12.30: Using AI tools for precision medicine and immunotherapy,
Pr Fabrice André,
Gustave Roussy, FR12.30-14.00 Lunch break and exhibition
14.00-16.00 Session IX:
Adaptive Immunity
(Pierre-Antoine Laurent)
14.00-14.30: Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality,
Pr Laurence Zitvogel,
Gustave Roussy, FR14.30-15.00: TBD
15.00-15.30: Emerging evidence for adapting radiotherapy to immunotherapy,
Pr Silvia Formenti,
Weill Cornell Medicine, USA15.30-16.00: TBD
16.00-16.30 Coffee break and exhibition
16.30-18.00 Session X:
Innate Immunity
(Lydia Meziani)
16.30-17.00: Low-dose ionizing γ-radiation elicits the extrusion of neutrophil extracellular traps,
Pr Ignacio Melero,
Clinica Universidad de Navarra, S17.00-17.30: TBD
17.30-18.00: TBD